
    
      The three proposed aims will evaluate the effect of four contraceptive methods (depot
      medroxyprogesterone acetate (DMPA), etonogestrel implant (Eng-Implant), levonorgestrel
      intrauterine device (Lng-IUD) and ParaGardÂ® T 380A Intrauterine Copper Contraceptive) on: (1)
      HIV target immune cells within the female genital mucosa; (2) markers of T-cell activation
      and trafficking within the female genital mucosa; and (3) secreted cytokines and chemokines
      within the female genital mucosa.
    
  